In Pursuit Of Hot Autoimmune Target, GlaxoSmithKline And Academics Team Up
Published: May 12, 2014
Drug targets are like fashion items. When a trendsetter proves one is worth spending money on, a lot of followers pile in. That’s no knock on drug developers, necessarily: When a new target shows some promise, it’s good to have lots of researchers with different ideas and approaches trying to find a drug to hit it. In the last few years, many of those researchers from the academic and industry camps who traditionally wouldn’t work together are joining forces. Enter drug giant GlaxoSmithKline (NYSE: GSK), which has tried various schemes to make its research groups more biotech-like, including the spin-out of an immunology team into a separate biotech company.
Help employers find you! Check out all the jobs and post your resume.